The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Open accessAbstract
BACKGROUND: Lipid-lowering therapy with statins reduces the risk of cardiovascular events, but the optimal level of low-density lipoprotein (LDL) cholesterol is unclear. METHODS: We enrolled 4162 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and compared 40 mg of pravastatin daily (standard therapy) with 80 mg of atorvastatin daily (intensive therapy). The primary end point was a composite of death from any cause, myocardial infarction, documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke. The study was designed to establish the noninferiority of pravastatin as compared with atorvastatin with respect to the time to an end-point event. Follow-up lasted 18 to 36 months (mean, 24). RESULTS: The median LDL cholesterol level achieved during treatment was 95 mg per deciliter (2.46 mmol per liter) in the standard-dose pravastatin group and 62 mg per deciliter (1.60 mmol per liter) in the high-dose atorvastatin group (P<0.001). Kaplan-Meier estimates of the rates of the primary end point at two years were 26.3 percent in the pravastatin group and 22.4 percent in the atorvastatin group, reflecting a 16 percent reduction in the hazard ratio in favor of atorvastatin (P=0.005; 95 percent confidence interval, 5 to 26 percent). The study did not meet the prespecified criterion for equivalence but did identify the superiority of the more intensive regimen. CONCLUSIONS: Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen. These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Likewise, in the PROVE-IT TIMI 22 trial, intensive lipid-lowering with atorvastatin 80 mg reduced LDL-C by 51% and triglycerides by 20%, compared with 22% and 11% reductions with pravastatin (40 mg/day) and was associated with greater protection against death or major cardiovascular events [72].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [72]
In the citing paper
“Lipid profile has long been considered among the most important risk factors for CVD in T2DM, and several trials have confirmed that lowering low-density lipoprotein cholesterol (LDL-C) via statins in T2DM was effective in reducing the risk of CVD [81, 82].”
From Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 (2018) · cites this paper as [81]
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [7]
In the citing paper
“Because cardiovascular event rates are increased in people with diabetes and established ASCVD, intensive therapy is indicated and has been shown to be of bene fi t in multiple large meta-analyses and randomized cardiovascular outcomes trials (91,99,105,107,108).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“These recommendations are based on the observation that high-intensity versus moderate-intensity statin therapy reduces cardiovascular event rates in high-risk individuals with established cardiovascular disease in randomized trials (95,107).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [107]
In the citing paper
“In the PACIFIC study740), which was a multicenter observational registry study on ACS, the incidence rate of fatal and nonfatal myocardial infarction was high, at 35/1,000 person-years, despite approximatively 80% subjects being administered statins.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“The results of these studies have found that, compared to patients with normal renal function, the risk for cardiovascular events, including cerebrovascular disease, cardiac death, and total mortality increases by 2–3-fold in those with CKD even when the CKD is mild.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [740]
In the citing paper
“Recent clinical trials in high-risk patients, such as those with acute coronary syndromes or previous cardiovascular events (200–202), have demonstrated that more aggressive therapy with high doses of statins to achieve an LDL cholesterol of <70 mg/dl led to a significant reduction in further events.”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [200]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D. J., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,475
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Research works printed but not linked: 1
- 1994, Lancet, 344, 1383
Cited by
Sorted by citations
Items 501–600 of 1,027
Vijan, S. S. (2015) · Annals of Internal Medicine · doi:10.7326/aitc201503030 · Cited by 126
Bach, R. G., Cannon, C. P., Giugliano, R. P., White, J. A., Lokhnygina, Y. V., Bohula, E. A., Califf, R. M., Braunwald, E., & Blazing, M. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.2306 · Cited by 126
Self-citationIbáñez, B., Vilahur, G., Cimmino, G., Speidl, W. S., Pinero, A., Choi, B. G., Zafar, M. U., Santos‐Gallego, C. G., Krause, B. R., Badimón, L., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.071 · Cited by 126
Stabilization of atherosclerotic plaques: an update
Ylä‐Herttuala, S., Bentzon, J. F., Daemen, M. J. A. P., Falk, E., García‐García, H. M., Herrmann, J., Hoefer, I. E., Jauhiainen, S., Jukema, J. W., Krams, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht301 · Cited by 127
Morrison, F. J. R. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.400 · Cited by 125
Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., & Rader, D. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.01.026 · Cited by 124
Self-citationPuri, R., Nissen, S. E., Libby, P., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Raichlen, J. S., Uno, K., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.004243 · Cited by 124
Clauss, S. B., Holmes, K. W., Hopkins, P. N., Stein, E. A., Cho, M., Tate, A. C., Johnson‐Levonas, A. O., & Kwiterovich, P. O. (2005) · PEDIATRICS · doi:10.1542/peds.2004-2090 · Cited by 124
Koskinas, K. C., Chatzizisis, Y. S., Baker, A. B., Edelman, E. R., Stone, P. H., & Feldman, C. L. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328331630b · Cited by 124
Racial Differences in the Cholesterol-Lowering Effect of Statin
Naito, R., Miyauchi, K., & Daida, H. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16004 · Cited by 123
Galectin‐3 Is a Potential Mediator for Atherosclerosis
Gao, Z., Liu, Z., Wang, R., Zheng, Y., Li, H., & Yang, L. M. (2020) · Journal of Immunology Research · doi:10.1155/2020/5284728 · Cited by 123
Ray, K. K., Cannon, C. P., Cairns, R., Morrow, D. A., Rifai, N., Kirtane, A. J., McCabe, C. H., Skene, A. M., Gibson, C. M., Ridker, P. M., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.024 · Cited by 123
Self-citationEckard, A. R., Jiang, Y., Debanne, S. M., Funderburg, N., & McComsey, G. A. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu012 · Cited by 122
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease
Hong, S., Lee, Y., Lee, S., Hong, B., Kang, W. C., Lee, J., Lee, J., Yang, T., Yoon, J., Ahn, C., et al. (2023) · JAMA · doi:10.1001/jama.2023.2487 · Cited by 122
Statins for prevention of atrial fibrillation after cardiac surgery: A systematic literature review
Liakopoulos, O. J., Choi, Y., Kuhn, E. W., Wittwer, T., Borys, M., Madershahian, N., Wassmer, G., & Wahlers, T. (2009) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.03.054 · Cited by 122
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Auer, J., Weber, T., & Eber, B. (2004) · New England Journal of Medicine · doi:10.1056/nejm200408123510719 · Cited by 122
Bots, M. L. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148472 · Cited by 121
Secretory Phospholipase A2-IIA and Cardiovascular Disease
Holmes, M. V., Simon, T., Exeter, H. J., Folkersen, L., Asselbergs, F. W., Guardiola, M., Cooper, J. A., Palmen, J., Hubacek, J. A., Carruthers, K. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.044 · Cited by 120
Self-citationFerreira, G. A., Navarro, T. P., Telles, R. W., Andrade, L. E. C., & Sato, E. I. (2007) · Rheumatology · doi:10.1093/rheumatology/kem186 · Cited by 120
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 120
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 120
Potential Benefits and Risks Associated with the Use of Statins
Khatiwada, N., & Hong, Z. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16020214 · Cited by 119
Nissen, S. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.013 · Cited by 119
Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057807 · Cited by 118
Vergallo, R., Ren, X., Yonetsu, T., Kato, K., Uemura, S., Yu, B., Jia, H., Abtahian, F., Aguirre, A. D., Tian, J., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.10.011 · Cited by 118
Lipids and lipid management in diabetes
Jaiswal, M., Schinske, A., & Pop‐Busui, R. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.12.001 · Cited by 118
Effect of combining psyllium fiber with simvastatin in lowering cholesterol
Moreyra, A. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1161 · Cited by 117
Apolipoproteins as markers and managers of coronary risk
Chan, D. C. (2006) · QJM · doi:10.1093/qjmed/hcl027 · Cited by 117
Myopathy in older people receiving statin therapy: a systematic review and meta‐analysis
Iwere, R. B., & Hewitt, J. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12687 · Cited by 116
Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients
Gitt, A. K., Lautsch, D., Ferrières, J., Kastelein, J. J. P., Drexel, H., Horack, M., Brudi, P., Vanneste, B., Bramlage, P., Chazelle, F., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.004 · Cited by 116
Clinical Use of Carotid Intima-Media Thickness: Review of the Literature
Hurst, R. T., Ng, D. W. C., Kendall, C. M., & Khandheria, B. K. (2007) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2007.02.028 · Cited by 116
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 115
The Vulnerable Atherosclerotic Plaque: Scope of the Literature
Alsheikh-Ali, A. A. A., Kitsios, G. D., Balk, E. M., Lau, J. W. Y., & Ip, S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-6-201009210-00272 · Cited by 115
Xinwei, J., Fu, X., Zhang, J., Gu, X., Ling, X., Weize, F., Guozhen, H., Yunfa, J., Weili, W., & Shi-qiang, L. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.04.014 · Cited by 115
McCullough, P. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03871106 · Cited by 115
Aberg, J. A., Zackin, R. A., Brobst, S. W., Evans, S. R., Alston, B., Henry, W. K., Glesby, M. J., Torriani, F. J., Yang, Y., Owens, S., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.757 · Cited by 115
Molecular basis of statin-associated myopathy
Vaklavas, C., Chatzizisis, Y. S., Ziakas, A., Zamboulis, C., & Giannoglou, G. D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.05.021 · Cited by 115
Fenofibrate: treatment of hyperlipidemia and beyond
Rosenson, R. S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1319 · Cited by 115
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Diabetes and Cardiovascular Disease: an Update
Almourani, R., Chinnakotla, B., Patel, R., Kurukulasuriya, L. R., & Sowers, J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1239-x · Cited by 114
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.541 · Cited by 114
Statins and the risk of new-onset diabetes
Preiss, D., & Sattar, N. A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834b4994 · Cited by 113
Yadav, M., Schiavone, N., Guzmán‐Aránguez, A., Giansanti, F., Papucci, L., de Lara, M. J. P., Singh, M., & Kaur, I. P. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00733-4 · Cited by 113
Emerging views of statin pleiotropy and cholesterol lowering
Yu, D., & Liao, J. K. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab032 · Cited by 113
Dyslipidemias in the Prevention of Cardiovascular Disease: Risks and Causality
Graham, I. M., Cooney, M. T., Bradley, D., Dudina, A. L., & Reiner, Ž. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0313-7 · Cited by 113
Beyond Medication Prescription as Performance Measures
Arnold, S. V., Spertus, J. A., Masoudi, F. A., Daugherty, S. L., Maddox, T. M., Li, Y., Dodson, J. A., & Chan, P. S. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.102 · Cited by 112
Cardiovascular Morbidity Associated with Nonadherence to Statin Therapy
Blackburn, D. F., Dobson, R. T., Blackburn, J. L., & Wilson, T. W. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.8.1035 · Cited by 112
van Mieghem, C. A. G., McFadden, E. P., de Feyter, P. J., Bruining, N., Schaar, J. A., Mollet, N. R., Cademartiri, F., Goedhart, D. M., de Winter, S., Rodríguez-Granillo, G. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.075 · Cited by 112
Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko, H. R., & King, S. B. (2008) · Circulation · doi:10.1161/circulationaha.106.667428 · Cited by 112
Mechanisms and assessment of statin‐related muscular adverse effects
Moßhammer, D., Schaeffeler, E., Schwab, M. G., & Mörike, K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12360 · Cited by 112
Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease
Srivastava, R. A. K. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3165-z · Cited by 113
Statins and inflammation: an update
Quist‐Paulsen, P. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283398e53 · Cited by 113
Sipahi, İ., Tuzcu, E. M., Wolski, K. E., Nicholls, S. J., Schoenhagen, P., Hu, B., Balog, C., Shishehbor, M. H., Magyar, W. A., Crowe, T. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-1-200707030-00003 · Cited by 111
Klf15 Deficiency Is a Molecular Link Between Heart Failure and Aortic Aneurysm Formation
Haldar, S. M., Lu, Y., Jeyaraj, D., Kawanami, D., Cui, Y., Eapen, S. J., Hao, C., Li, Y., Doughman, Y., Watanabe, M., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000502 · Cited by 111
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
Role of disease risk scores in comparative effectiveness research with emerging therapies
Glynn, R. J., Gagne, J. J., & Schneeweiß, S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3231 · Cited by 110
Hermida, N., & Balligand, J. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5537 · Cited by 110
Sasaki, J. D., Ikeda, Y., Kuribayashi, T., Kajiwara, K., Biro, S., Yamamoto, K., Ageta, M., Kobori, S., Saikawa, T., Otonari, T., et al. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.05.017 · Cited by 110
Dual role of lipoproteins in endothelial cell dysfunction in atherosclerosis
Stancu, C. S., Toma, L., & Sima, A. V. (2012) · Cell and Tissue Research · doi:10.1007/s00441-012-1437-1 · Cited by 110
Thrane, P. G., Olesen, K. K. W., Thim, T., Gyldenkerne, C., Mortensen, M. B., Kristensen, S. D., & Mæng, M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.025 · Cited by 109
SEARCH Study Collaborative Group (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.034 · Cited by 110
Lee, K. H., Jeong, M. H., Kim, H. M., Ahn, Y., Kim, J., Chae, S. C., Kim, Y. J., Hur, S., Seong, I. W., Hong, T. J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.05.057 · Cited by 109
Zhou, Z., Rahme, E., & Pilote, L. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.003 · Cited by 109
Madder, R. D., Smith, J. L., Dixon, S. R., & Goldstein, J. A. (2012) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.963934 · Cited by 108
Oswald, S., Haenisch, S., Fricke, C., Sudhop, T., Remmler, C., Gießmann, T., Jedlitschky, G., Adam, U., Dazert, E., & Warzok, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.004 · Cited by 108
Catapano, A. L., Davidson, M. H., Ballantyne, C. M., Brady, W. E., Gazzara, R. A., Tomassini, J. E., & Tershakovec, A. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132721 · Cited by 108
Yu, M., Liang, C., Kong, Q., Wang, Y., & Li, M. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-019-1182-5 · Cited by 107
Hong, M., Park, D., Lee, C.-W., Lee, S., Kim, Y., Kang, D., Song, J., Kim, J., Park, S., & Park, S.-J. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.03.015 · Cited by 107
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.006 · Cited by 107
Kulik, A., Voisine, P., Mathieu, P., Masters, R. G., Mesana, T. G., May, M. R. L., & Ruel, M. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.107 · Cited by 107
Hepatic and Cardiovascular Consequences of Familial Hypobetalipoproteinemia
Sankatsing, R. R., Fouchier, S. W., de Haan, S., Hutten, B. A., de Groot, E., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000176191.64314.07 · Cited by 106
Recent Update to the US Cholesterol Treatment Guidelines
Nayor, M. G., & Vasan, R. S. (2016) · Circulation · doi:10.1161/circulationaha.116.021407 · Cited by 106
Feringa, H. H. H., Karagiannis, S. E., van Waning, V. H., Boersma, E. H., Schouten, O., Bax, J. J., & Poldermans, D. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.01.024 · Cited by 106
Vulnerable Plaque: Definition, Diagnosis, and Treatment
Moreno, P. (2009) · Cardiology Clinics · doi:10.1016/j.ccl.2009.09.008 · Cited by 106
Lester, S. J., Eleid, M. F., Khandheria, B. K., & Hurst, R. T. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.229 · Cited by 106
Karlson, B. W., Palmer, M. K., Nicholls, S. J., Lundman, P., & Barter, P. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.011 · Cited by 105
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 105
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
Shapiro, M. D., & Fazio, S. (2017) · F1000Research · doi:10.12688/f1000research.9845.1 · Cited by 103
Dehbi, H., Royston, P. J., & Hackshaw, A. K. (2017) · BMJ · doi:10.1136/bmj.j2250 · Cited by 105
Chamberlain, J. J., Johnson, E. L., Leal, S., Rhinehart, A. S., Shubrook, J. H., & Peterson, L. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0222 · Cited by 105
Murphy, S. A., Pedersen, T. R., Gaciong, Z. A., Češka, R., Владиславович, Е. М., Connolly, D. L., Jukema, J. W., Tóth, K., Tikkanen, M. J., Im, K., et al. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0886 · Cited by 105
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
Intensive Multifactorial Intervention for Stable Coronary Artery Disease
Maron, D. J., Boden, W. E., O’Rourke, R. A., Hartigan, P. M., Calfas, K. J., Mancini, G. B. J., Spertus, J. A., Dada, M. R., Kostuk, W. J., Knudtson, M. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.062 · Cited by 105
Dyslipidemia in women: etiology and management
Toth, P. P., & Phan, B. A. P. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s38133 · Cited by 104
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht260 · Cited by 104
Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 104
Barriers to cardiovascular disease risk scoring and primary prevention in Europe
Hobbs, R. F., Jukema, J. W., Silva, P. M. D., McCormack, T., & Catapano, A. L. (2010) · QJM · doi:10.1093/qjmed/hcq122 · Cited by 104
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
Gopal, K., Johnson, T. C., Gopal, S. K., Walfish, A., Bang, C. T., Suwandhi, P., Sahdala, H. N. P., Clain, D. J., Bodenheimer, H. C., & Min, A. D. (2006) · Hepatology · doi:10.1002/hep.21261 · Cited by 104
High-Dose Statins in Acute Coronary Syndromes
Nissen, S. E. (2004) · JAMA · doi:10.1001/jama.292.11.1365 · Cited by 104
Macin, S. M., Perna, E. R., Farías, E. F., Franciosi, V. A., Cialzeta, J., Brizuela, M., Medina, F., Tajer, C. D., Doval, H. C., & Badaracco, J. R. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.07.041 · Cited by 103
Tsubokawa, T., Yagi, K., Nakanishi, C., Zuka, M., Nohara, A., Ino, H., Fujino, N., Konno, T., Kawashiri, M., Ishibashi‐Ueda, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01330.2008 · Cited by 103
Heart Protection Study Collaborative Group (2005) · BMC Medicine · doi:10.1186/1741-7015-3-6 · Cited by 103
Berwanger, O. B., Guimarães, H. P., Laranjeira, L. N., Cavalcanti, A. B., Kodama, A. A., Zazula, A. D., Santucci, E. V., Victor, E. D. S., Tenuta, M., Carvalho, V. O., et al. (2012) · JAMA · doi:10.1001/jama.2012.413 · Cited by 102
Rethinking Primary Prevention of Atherosclerosis-Related Diseases
Claudio Napoli, A., Lerman, L. O., de Nigris, F., Gössl, M., Balestrieri, M. L., & Lerman, A. (2006) · Circulation · doi:10.1161/circulationaha.105.570358 · Cited by 102
Kaneda, A., Wang, C. J., Cheong, R., Timp, W., Onyango, P. O., Wen, B., Iacobuzio–Donahue, C. A., OHLSSON, R. I., Andraos, R., Pearson, M. A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710359105 · Cited by 102
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
Investigation of Microencapsulated BSH ActiveLactobacillusin the Simulated Human GI Tract
Martoni, C., Bhathena, J., Jones, M. L., Urbanska, A. M., Chen, H., & Prakash, S. (2007) · BioMed Research International · doi:10.1155/2007/13684 · Cited by 101
Muntner, P., DeSalvo, K. B., Wildman, R. P., Raggi, P., He, J., & Whelton, P. K. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj124 · Cited by 101
Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport
Duffy, D., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.105.593855 · Cited by 101
Self-citationThompson, P. L., Meredith, I. T., Amerena, J. V., Campbell, T. J., Sloman, J. G., & Harris, P. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.10.052 · Cited by 101
Metadata
- Authors
- Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- University of Pennsylvania (US)
- Université de Montréal (CA)
- Bristol-Myers Squibb (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-04-08
- Volume
- 350
- Issue
- 15
- Pages
- 1495-1504
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159449551
- Cited by
- 4,938
- References
- 32
- Citations by year
- 2026: 87 · 2025: 84 · 2024: 121 · 2023: 117 · 2022: 120 · 2021: 129 · 2020: 147 · 2019: 163 · 2018: 155 · 2017: 215 · 2016: 178 · 2015: 216 · 2014: 213 · 2013: 215 · 2012: 229
- FWCI
- 442.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- acute coronary syndrome, statins, intensive lipid-lowering therapy, LDL cholesterol, pravastatin, atorvastatin, non-inferiority, major adverse cardiovascular events, revascularization, myocardial infarction, stroke, unstable angina
- MeSH terms
- Atorvastatin, Angina, Unstable, Anticholesteremic Agents, Cardiovascular Diseases, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
